ArriVent BioPharma expands at-the-market equity program by up to $250M

ArriVent BioPharma, Inc.

• Filed prospectus supplement on May 11, 2026 to sell up to $250,000,000 of common stock via ATM.
• Jefferies LLC named as sales agent under existing Open Market Sale Agreement dated Feb 3, 2025.
• Proceeds will be used for general corporate purposes; no specific use disclosed.
• Offering is made under automatic shelf registration statement (Form S-3ASR, File 333-284661).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.